Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056
University Hospital of Lausanne · Université Claude Bernard Lyon 1 · +13 more institutions
Abstract
Fragile X syndrome (FXS) is an X-linked condition associated with intellectual disability and behavioral problems. It is caused by expansion of a CGG repeat in the 5' untranslated region of the fragile X mental retardation 1 (FMR1) gene. This mutation is associated with hypermethylation at the FMR1 promoter and resultant transcriptional silencing. FMR1 silencing has many consequences, including up-regulation of metabotropic glutamate receptor 5 (mGluR5)-mediated signaling. mGluR5 receptor antagonists have shown promise in preclinical FXS models and in one small open-label study of FXS. We examined whether a receptor subtype-selective inhibitor of mGluR5, AFQ056, improves the behavioral symptoms of FXS in a…
Citation impact
- FWCI
- 63.57
- Percentile
- 100%
- References
- 22
Authors
26- SJSébastien JacquemontCorresponding
University Hospital of Lausanne
- ACAurore CurieCorresponding
Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Hospices Civils de Lyon, Laboratoire sur le Langage, le Cerveau et la Cognition
- VDVincent des Portes
Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Hospices Civils de Lyon, Laboratoire sur le Langage, le Cerveau et la Cognition
- MGMaria Giulia Torrioli
Università Cattolica del Sacro Cuore
- EBElizabeth Berry‐Kravis
Rush University Medical Center
Topics & keywords
- Fragile X syndrome
- Metabotropic glutamate receptor 5
- FMR1
- Antagonist
- Epigenetics
- Metabotropic glutamate receptor
- Glutamate receptor
- Medicine
- Good health and well-being